Abstract 399: NCI Office of Cancer Genomics: Supporting structural and functional genomics and development of bioinformatic approaches to advance precision oncology
Authors: Pamela C. Birriel, Caitlyn W. Barrett, Tanja M. Davidsen, Martin L. Ferguson, Patee Gesuwan, Nicholas B. Griner, Jaime M. Guidry Auvil, Yiwen He, Subhashini Jagu, Freddie L. Pruitt, Daniela S. Gerhard
Journal: Cancer Research (2018)

Abstract The National Cancer Institute's Office of Cancer Genomics (OCG) aims to advance the molecular understanding of cancer, with the goal of improving clinical outcomes. OCG supports large-scale cancer genomics and translational research programs that share data and resources with the research community, thereby accelerating discoveries into the clinic and contributing to precision oncology. The OCG initiatives promote: i) generation and dissemination of molecular and clinical data via programmatic databases and the Genomic Data Commons, ii) advances in bio- and chemi-informatic methodologies, and iii) creation of valuable experimental reagents, resources, models, and standard operating procedures. OCG currently supports four innovative and collaborative programs which conjointly generate, analyze, and translate genomic and other datasets into biologically and clinically-relevant information for the scientific and medical communities. The Cancer Genome Characterization Initiative (CGCI) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiatives use comprehensive genomic, transcriptomic, and epigenomic approaches to analyze tumor and patient matched normal tissue samples with the goal of identifying therapeutic targets and biomarkers. CGCI characterizes both adult and pediatric cancers, including those prevalent in HIV-positive individuals, while TARGET focuses predominantly on high-risk cancers affecting children and young adults. The Cancer Target Discovery and Development (CTD2) Network advances cancer research by bridging the knowledge gap between cancer genomics and precision oncology for the development of effective combinatorial cancer treatments to minimize treatment resistance. The Network develops bioinformatics and analysis tools, generates diverse datasets, and further validates subsets of these data. The Human Cancer Models Initiative (HCMI) is an international consortium which will develop next generation patient-derived cancer models that are representative of the biology and complexity of human tumors. Models will be molecularly characterized and clinically annotated, and models along with the data will be available as a community resource. Data, analytical tools, and resources generated by OCG programs are made available through the OCG website (https://ocg.cancer.gov/) to the research community to accelerate the discovery of efficient treatment strategies for cancer. This poster will include an overview of the programs and emphasize the usability and functionality of the OCG databases and resources. Presenters will also provide data access information and examples of past data use highlighting the benefit of the OCG programs to the scientific community. Citation Format: Pamela C. Birriel, Caitlyn W. Barrett, Tanja M. Davidsen, Martin L. Ferguson, Patee Gesuwan, Nicholas B. Griner, Jaime M. Guidry Auvil, Yiwen He, Subhashini Jagu, Freddie L. Pruitt, Daniela S. Gerhard. NCI Office of Cancer Genomics: Supporting structural and functional genomics and development of bioinformatic approaches to advance precision oncology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 399.